Shares of Amesite Inc. (NASDAQ:AMST) jumped 100% after the company reported a 63% revenue increase for its NurseMagic™ platform, fueled by the rollout of its census-based Enterprise subscription model.

The AI-driven enterprise solutions provider said Enterprise sales have now overtaken its B2C business, reflecting stronger adoption among post-acute care providers seeking scalable tools to secure full reimbursement rates. Alongside the update, Amesite also introduced a new AI-powered automated form-fill product designed for required government documentation.

Brandon Owens, Amesite’s VP of Sales, highlighted the company’s shift in focus: from selling directly to individual employees to covering entire patient populations across healthcare systems. The expansion comes ahead of the Centers for Medicare & Medicaid Services (CMS) mandate in October requiring the Hospice Outcomes and Patient Evaluation (HOPE) assessment, which is expected to significantly increase documentation workloads.

The company said its AI-enabled HOPE automation solution, part of NurseMagic™ Enterprise, can auto-populate detailed forms, cut administrative time, and help providers maximize reimbursements.

Unlike traditional electronic medical record (EMR) vendors, Amesite’s strategy centers on providing AI-driven compliance solutions tailored for post-acute care. The firm noted that this segment is expanding at an annual rate of 8%, outpacing the growth of the acute care market.

Amesite stock price

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.